Cargando…

Staging investigations for oesophageal cancer: a meta-analysis

The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles publishe...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vliet, E P M, Heijenbrok-Kal, M H, Hunink, M G M, Kuipers, E J, Siersema, P D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243147/
https://www.ncbi.nlm.nih.gov/pubmed/18212745
http://dx.doi.org/10.1038/sj.bjc.6604200
_version_ 1782150620346580992
author van Vliet, E P M
Heijenbrok-Kal, M H
Hunink, M G M
Kuipers, E J
Siersema, P D
author_facet van Vliet, E P M
Heijenbrok-Kal, M H
Hunink, M G M
Kuipers, E J
Siersema, P D
author_sort van Vliet, E P M
collection PubMed
description The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT, and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT, and FDG-PET for regional lymph node metastases were 0.80 (95% confidence interval 0.75–0.84), 0.50 (0.41–0.60), and 0.57 (0.43–0.70), respectively, and specificities were 0.70 (0.65–0.75), 0.83 (0.77–0.89), and 0.85 (0.76–0.95), respectively. Diagnostic performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and specificity were 0.85 (0.72–0.99) and 0.96 (0.92–1.00), respectively. For abdominal lymph node metastases by CT, these values were 0.42 (0.29–0.54) and 0.93 (0.86–1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62–0.79) and 0.93 (0.89–0.97) for FDG-PET and 0.52 (0.33–0.71) and 0.91 (0.86–0.96) for CT, respectively. Diagnostic performance of FDG-PET for distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients. For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining the location(s).
format Text
id pubmed-2243147
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22431472009-09-10 Staging investigations for oesophageal cancer: a meta-analysis van Vliet, E P M Heijenbrok-Kal, M H Hunink, M G M Kuipers, E J Siersema, P D Br J Cancer Clinical Study The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography (CT), and (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT, and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT, and FDG-PET for regional lymph node metastases were 0.80 (95% confidence interval 0.75–0.84), 0.50 (0.41–0.60), and 0.57 (0.43–0.70), respectively, and specificities were 0.70 (0.65–0.75), 0.83 (0.77–0.89), and 0.85 (0.76–0.95), respectively. Diagnostic performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and specificity were 0.85 (0.72–0.99) and 0.96 (0.92–1.00), respectively. For abdominal lymph node metastases by CT, these values were 0.42 (0.29–0.54) and 0.93 (0.86–1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62–0.79) and 0.93 (0.89–0.97) for FDG-PET and 0.52 (0.33–0.71) and 0.91 (0.86–0.96) for CT, respectively. Diagnostic performance of FDG-PET for distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients. For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining the location(s). Nature Publishing Group 2008-02-12 2008-01-22 /pmc/articles/PMC2243147/ /pubmed/18212745 http://dx.doi.org/10.1038/sj.bjc.6604200 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
van Vliet, E P M
Heijenbrok-Kal, M H
Hunink, M G M
Kuipers, E J
Siersema, P D
Staging investigations for oesophageal cancer: a meta-analysis
title Staging investigations for oesophageal cancer: a meta-analysis
title_full Staging investigations for oesophageal cancer: a meta-analysis
title_fullStr Staging investigations for oesophageal cancer: a meta-analysis
title_full_unstemmed Staging investigations for oesophageal cancer: a meta-analysis
title_short Staging investigations for oesophageal cancer: a meta-analysis
title_sort staging investigations for oesophageal cancer: a meta-analysis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243147/
https://www.ncbi.nlm.nih.gov/pubmed/18212745
http://dx.doi.org/10.1038/sj.bjc.6604200
work_keys_str_mv AT vanvlietepm staginginvestigationsforoesophagealcancerametaanalysis
AT heijenbrokkalmh staginginvestigationsforoesophagealcancerametaanalysis
AT huninkmgm staginginvestigationsforoesophagealcancerametaanalysis
AT kuipersej staginginvestigationsforoesophagealcancerametaanalysis
AT siersemapd staginginvestigationsforoesophagealcancerametaanalysis